HRP20160166T1 - Derivat pirolidin-3-iloctene kiseline - Google Patents
Derivat pirolidin-3-iloctene kiseline Download PDFInfo
- Publication number
- HRP20160166T1 HRP20160166T1 HRP20160166TT HRP20160166T HRP20160166T1 HR P20160166 T1 HRP20160166 T1 HR P20160166T1 HR P20160166T T HRP20160166T T HR P20160166TT HR P20160166 T HRP20160166 T HR P20160166T HR P20160166 T1 HRP20160166 T1 HR P20160166T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- pharmaceutically acceptable
- acceptable salt
- carbamoyl
- acetic acid
- Prior art date
Links
- OUENRUZPZZFMCA-UHFFFAOYSA-N 2-pyrrolidin-1-ium-3-ylacetate Chemical class OC(=O)CC1CCNC1 OUENRUZPZZFMCA-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- NDYGUVWYIVLZCY-HFJWLAOPSA-N 2-[(3s,4r)-1-[(2,6-dichlorophenyl)methyl]-3-[[1-[(4,4-difluorocyclohexyl)methyl]piperidin-4-yl]carbamoyl]-4-methylpyrrolidin-3-yl]acetic acid Chemical compound C([C@@H]([C@](C1)(CC(O)=O)C(=O)NC2CCN(CC3CCC(F)(F)CC3)CC2)C)N1CC1=C(Cl)C=CC=C1Cl NDYGUVWYIVLZCY-HFJWLAOPSA-N 0.000 claims 2
- WYNQAMDWWABRGP-RBTNQOKQSA-N 2-[(3s,4r)-1-[(2-chloro-6-methylphenyl)methyl]-3-[[1-(cyclohexen-1-ylmethyl)piperidin-4-yl]carbamoyl]-4-methylpyrrolidin-3-yl]acetic acid Chemical compound C([C@@H]([C@](C1)(CC(O)=O)C(=O)NC2CCN(CC=3CCCCC=3)CC2)C)N1CC1=C(C)C=CC=C1Cl WYNQAMDWWABRGP-RBTNQOKQSA-N 0.000 claims 2
- QQFJWVDGLRZHFD-CCLHPLFOSA-N 2-[(3s,4r)-1-[(2-chloro-6-methylphenyl)methyl]-3-[[1-(cyclopenten-1-ylmethyl)piperidin-4-yl]carbamoyl]-4-methylpyrrolidin-3-yl]acetic acid Chemical compound C([C@@H]([C@](C1)(CC(O)=O)C(=O)NC2CCN(CC=3CCCC=3)CC2)C)N1CC1=C(C)C=CC=C1Cl QQFJWVDGLRZHFD-CCLHPLFOSA-N 0.000 claims 2
- OYZBJRPMFFOVPU-STTRJGPESA-N 2-[(3s,4r)-3-[[(3s)-1-(cyclohexen-1-ylmethyl)pyrrolidin-3-yl]carbamoyl]-1-[(2,6-dichlorophenyl)methyl]-4-methylpyrrolidin-3-yl]acetic acid Chemical compound C([C@@H]([C@](C1)(CC(O)=O)C(=O)N[C@@H]2CN(CC=3CCCCC=3)CC2)C)N1CC1=C(Cl)C=CC=C1Cl OYZBJRPMFFOVPU-STTRJGPESA-N 0.000 claims 2
- VOVPPVIWFOTZMW-UZTOHYMASA-N 2-[(3s,4r)-3-[[1-(cyclohexen-1-ylmethyl)piperidin-4-yl]carbamoyl]-1-[(2,6-dichlorophenyl)methyl]-4-methylpyrrolidin-3-yl]acetic acid Chemical compound C([C@@H]([C@](C1)(CC(O)=O)C(=O)NC2CCN(CC=3CCCCC=3)CC2)C)N1CC1=C(Cl)C=CC=C1Cl VOVPPVIWFOTZMW-UZTOHYMASA-N 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 2
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- LKEMIIDHXHVBHO-UZTOHYMASA-N 2-[(3s,4r)-1-[[2-chloro-6-(difluoromethyl)phenyl]methyl]-3-[(1-hexylpiperidin-4-yl)carbamoyl]-4-methylpyrrolidin-3-yl]acetic acid Chemical compound C1CN(CCCCCC)CCC1NC(=O)[C@@]1(CC(O)=O)[C@@H](C)CN(CC=2C(=CC=CC=2Cl)C(F)F)C1 LKEMIIDHXHVBHO-UZTOHYMASA-N 0.000 claims 1
- MPAOAAFSKXVAHW-HMILPKGGSA-N 2-[(3s,4r)-1-[[2-chloro-6-(difluoromethyl)phenyl]methyl]-3-[[1-(cyclohexen-1-ylmethyl)piperidin-4-yl]carbamoyl]-4-methylpyrrolidin-3-yl]acetic acid Chemical compound C([C@@H]([C@](C1)(CC(O)=O)C(=O)NC2CCN(CC=3CCCCC=3)CC2)C)N1CC1=C(Cl)C=CC=C1C(F)F MPAOAAFSKXVAHW-HMILPKGGSA-N 0.000 claims 1
- ZXRUHYZEZUIQGS-HMILPKGGSA-N 2-[(3s,4r)-1-[[2-chloro-6-(difluoromethyl)phenyl]methyl]-3-[[1-(cyclohexylmethyl)piperidin-4-yl]carbamoyl]-4-methylpyrrolidin-3-yl]acetic acid Chemical compound C([C@@H]([C@](C1)(CC(O)=O)C(=O)NC2CCN(CC3CCCCC3)CC2)C)N1CC1=C(Cl)C=CC=C1C(F)F ZXRUHYZEZUIQGS-HMILPKGGSA-N 0.000 claims 1
- FHKAMPYJDLORMJ-XRHLQHRESA-N 2-[(3s,4r)-1-[[2-chloro-6-(difluoromethyl)phenyl]methyl]-3-[[1-(cyclopenten-1-ylmethyl)piperidin-4-yl]carbamoyl]-4-methylpyrrolidin-3-yl]acetic acid Chemical compound C([C@@H]([C@](C1)(CC(O)=O)C(=O)NC2CCN(CC=3CCCC=3)CC2)C)N1CC1=C(Cl)C=CC=C1C(F)F FHKAMPYJDLORMJ-XRHLQHRESA-N 0.000 claims 1
- JXBBOBNZJSUUDJ-BNSZOAOKSA-N 2-[(3s,4r)-1-[[2-chloro-6-(trifluoromethyl)phenyl]methyl]-3-[[1-(2-fluoropentyl)piperidin-4-yl]carbamoyl]-4-methylpyrrolidin-3-yl]acetic acid Chemical compound C1CN(CC(F)CCC)CCC1NC(=O)[C@@]1(CC(O)=O)[C@@H](C)CN(CC=2C(=CC=CC=2Cl)C(F)(F)F)C1 JXBBOBNZJSUUDJ-BNSZOAOKSA-N 0.000 claims 1
- JTJKDYLEMNXXER-UZTOHYMASA-N 2-[(3s,4r)-1-[[2-chloro-6-(trifluoromethyl)phenyl]methyl]-3-[[1-(cyclohexen-1-ylmethyl)piperidin-4-yl]carbamoyl]-4-methylpyrrolidin-3-yl]acetic acid Chemical compound C([C@@H]([C@](C1)(CC(O)=O)C(=O)NC2CCN(CC=3CCCCC=3)CC2)C)N1CC1=C(Cl)C=CC=C1C(F)(F)F JTJKDYLEMNXXER-UZTOHYMASA-N 0.000 claims 1
- DSKULBBWMLJIIN-HFJWLAOPSA-N 2-[(3s,4r)-1-[[2-chloro-6-(trifluoromethyl)phenyl]methyl]-3-[[1-(cyclopenten-1-ylmethyl)piperidin-4-yl]carbamoyl]-4-methylpyrrolidin-3-yl]acetic acid Chemical compound C([C@@H]([C@](C1)(CC(O)=O)C(=O)NC2CCN(CC=3CCCC=3)CC2)C)N1CC1=C(Cl)C=CC=C1C(F)(F)F DSKULBBWMLJIIN-HFJWLAOPSA-N 0.000 claims 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 claims 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 claims 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102100020997 Fractalkine Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- -1 difluorocyclohexyl group Chemical group 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005817 fluorobutyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 230000012743 protein tagging Effects 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Claims (22)
1. Spoj prikazan s formulom (1) ili njegova farmaceutski prihvatljiva sol:
[image]
naznačen time da R predstavlja skupinu C1-6 alkil nesupstituiranu ili koja ima 1 do 3 supstituenta odabrana od halogenih atoma, skupinu C3-8 cikloalkil nesupstituiranu ili koja ima 1 do 3 supstituenta odabrana od halogenih atoma, ili skupinu C3-8 cikloalkenil nesupstituiranu ili koja ima 1 do 3 supstituenta odabrana od halogenih atoma,
X predstavlja C1-6 alkil skupinu,
Y i Z su isti ili različiti jedan od drugog i svaki predstavlja halogeni atom ili skupinu C1-6 alkil nesupstituiranu ili koja ima 1 do 3 supstituenta odabrana od halogenih atoma,
n predstavlja 0 ili 1.
2. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time da R je fluorobutil skupina, pentil skupina, cikloheksil skupina, difluorocikloheksil skupina, ciklopentenil skupina ili cikloheksenil skupina.
3. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1 ili 2, naznačen time da X je metilna skupina.
4. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 3, naznačen time da Y je atom klora.
5. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 4, naznačen time da Z je atom klora, metilna skupina, difluorometilna skupina ili trifluorometilna skupina.
6. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 5, naznačen time da n je 1.
7. Spoj prema zahtjevu 1, naznačen time da je odabran iz skupine koju čine:
2-[(3S,4R)-1-{[2-kloro-6-(trifluorometil)fenil]metil}-3-{[1-(2-fluoropentil)piperidin-4-il]karbamoil}-4-metilpirolidin-3-il]octena kiselina,
2-[(3S,4R)-1-[(2,6-diklorofenil)metil]-3-({1-[(4,4-difluorocikloheksil)metil]piperidin-4-il}karbamoil)-4-metilpirolidin-3-il]octena kiselina,
2-[(3S,4R)-1-{[2-kloro-6-(trifluorometil)fenil]metil}-3-{[1-(cikloheks-1-en-1-ilmetil)piperidin-4-il]karbamoil}-4-metilpirolidin-3-il]octena kiselina,
2-[(3S,4R)-1-[(2-kloro-6-metilfenil)metil]-3-{[1-(cikloheks-1-en-1-ilmetil)piperidin-4-il]karbamoil}-4-metilpirolidin-3-il]octena kiselina,
2-[(3S,4R)-1-{[2-kloro-6-(trifluorometil)fenil]metil}-3-{[1-(ciklopent-1-en-1-ilmetil)piperidin-4-il]karbamoil}-4-metilpirolidin-3-il]octena kiselina,
2-[(3S,4R)-1-[(2-kloro-6-metilfenil)metil]-3-{[(1-ciklopent-1-en-1-ilmetil)piperidin-4-il]karbamoil}-4-metilpirolidin-3-il]octena kiselina,
2-[(3S,4R)-3-{[(3S)-1-(cikloheks-1-en-1-ilmetil)pirolidin-3-il]karbamoil}-1-[(2,6-diklorofenil)metil]-4-metilpirolidin-3-il]octena kiselina,
2-[(3S,4R)-1-{[2-kloro-6-(difluorometil)fenil]metil}-3-[(1-heksilpiperidin-4-il)karbamoil]-4-metilpirolidin-3-il]octena kiselina,
2-[(3S,4R)-3-{[(1-cikloheks-1-en-1-ilmetil)piperidin-4-il]karbamoil}-1-[(2,6-diklorofenil)metil]-4-metilpirolidin-3-il]octena kiselina,
2-[(3S,4R)-1-{[2-kloro-6-(difluorometil)fenil]metil}-3-{[1-(cikloheks-1-en-1-ilmetil)piperidin-4-il]karbamoil}-4-metilpirolidm-3-il]octena kiselina,
2-[(3S,4R)-1-{[2-kloro-6-(difluorometil)fenil]metil}-3-{[1-(ciklopent-1-en-1-ilmetil)piperidin-4-il]karbamoil}-4-metilpirolidin-3-il]octena kiselina i
2-[(3S,4R)-1-{[2-kloro-6-(difluorometil)fenil]metil}-3-{[1-(cikloheksilmetil)piperidin-4-il]karbamoil}-4-metilpirolidin-3-il]octena kiselina,
ili njegova farmaceutski prihvatljiva sol
8. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 7 naznačen time da je za uporabu za terapiju.
9. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 7 naznačen time da je za uporabu za liječenje upalne bolesti crijeva.
10. Spoj ili njegova farmaceutski prihvatljiva sol za uporabu prema zahtjevu 9, naznačen time da upalna bolest crijeva je ulcerativni kolitis ili Crohnova bolest.
11. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 7, naznačen time da se koristi kao inhibitor fraktalkin-CX3CR1 puta.
12. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 7, naznačen time da se koristi kao inhibitor fraktalkina.
13. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 7, naznačen time da se koristi kao inhibitor CX3CR1.
14. Medikament naznačen time da sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1 do 7.
15. Uporaba spoja prema zahtjevu 1, naznačen time da se kao kemijski test radi identifikacije označenih proteina uvodi bilo koja od (1) skupine za označavanje proteina, (2) a cleavable linker, (3) a fishing tag group, (4) odredive oznake, te (5) skupine vezane na nosače krute faze.
16. Spoj prema zahtjevu 1, naznačen time da je 2-[(3S,4R)-1-[(2,6-diklorofenil)metil]-3-({1-[(4,4-difluorocikloheksil)metil]piperidin-4-il}karbamoil)-4-metilpirolidin-3-il]octena kiselina ili njegova farmaceutski prihvatljiva sol:
[image]
17. Spoj prema zahtjevu 1, naznačen time da je 2-[(3S,4R)-1-{[2-kloro-6-(trifluorometil)fenil]metil}-3-{[1-(cikloheks-1-en-1-ilmetil)piperidin-4-il]karbamoil}-4-metilpirolidin-3-il]octena kiselina ili njegova farmaceutski prihvatljiva sol:
[image]
18. Spoj prema zahtjevu 1, naznačen time da je 2-[(3S,4R)-1-[(2-kloro-6-metilfenil)metil]-3-{[1-(cikloheks-1-en-1-ilmetil)piperidin-4-il]karbamoil}-4-metilpirolidin-3-il]octena kiselina ili njegova farmaceutski prihvatljiva sol:
[image]
19. Spoj prema zahtjevu 1, naznačen time da je 2-[(3S,4R)-1-{[2-kloro-6-(trifluorometil)fenil]metil}-3-{[1-(ciklopent-1-en-1-ilmetil)piperidin-4-il]karbamoil)-4-metilpirolidin-3-il]octena kiselina ili njegova farmaceutski prihvatljiva sol:
[image]
20. Spoj prema zahtjevu 1, naznačen time da je 2-[(3S,4R)-1-[(2-kloro-6-metilfenil)metil]-3-{[(1-ciklopent-1-en-1-ilmetil)piperidin-4-il]karbamoil}-4-metilpirolidin-3-il]octena kiselina ili njegova farmaceutski prihvatljiva sol:
[image]
21. Spoj prema zahtjevu 1, naznačen time da je 2-[(3S,4R)-3-{[(3S)-1-(cikloheks-1-en-1-ilmetil)pirolidin-3-il]karbamoil}-1-[(2,6-diklorofenil)metil]-4-metilpirolidin-3-il]octena kiselina ili njegova farmaceutski prihvatljiva sol:
[image]
22. Spoj prema zahtjevu 1, naznačen time da je 2-[(3S,4R)-3-{[(1-cikloheks-1-en-1-ilmetil)piperidin-4-il]karbamoil}-1-[(2,6-diklorofenil)metil]-4-metilpirolidin-3-il]octena kiselina ili njegova farmaceutski prihvatljiva sol:
[image]
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011199482 | 2011-09-13 | ||
| EP12831085.1A EP2757103B1 (en) | 2011-09-13 | 2012-09-11 | Pyrrolidine-3-ylacetic acid derivative |
| PCT/JP2012/073171 WO2013039057A1 (ja) | 2011-09-13 | 2012-09-11 | ピロリジン－３－イル酢酸誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160166T1 true HRP20160166T1 (hr) | 2016-03-11 |
Family
ID=47883287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160166TT HRP20160166T1 (hr) | 2011-09-13 | 2016-02-16 | Derivat pirolidin-3-iloctene kiseline |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP2757103B1 (hr) |
| JP (1) | JP5829689B2 (hr) |
| KR (1) | KR101963922B1 (hr) |
| CN (1) | CN103764648B (hr) |
| AR (1) | AR087788A1 (hr) |
| AU (1) | AU2012309556B2 (hr) |
| BR (1) | BR112014004267B1 (hr) |
| CA (1) | CA2844617C (hr) |
| CL (1) | CL2014000484A1 (hr) |
| CY (1) | CY1117460T1 (hr) |
| DK (1) | DK2757103T3 (hr) |
| ES (1) | ES2564732T3 (hr) |
| HK (1) | HK1193407A1 (hr) |
| HR (1) | HRP20160166T1 (hr) |
| HU (1) | HUE026824T2 (hr) |
| IL (1) | IL230804A (hr) |
| JO (1) | JO3082B1 (hr) |
| ME (1) | ME02383B (hr) |
| MX (1) | MX358494B (hr) |
| MY (1) | MY169869A (hr) |
| PE (1) | PE20141353A1 (hr) |
| PL (1) | PL2757103T3 (hr) |
| PT (1) | PT2757103E (hr) |
| RS (1) | RS54582B1 (hr) |
| RU (1) | RU2615135C2 (hr) |
| SG (1) | SG11201400163WA (hr) |
| SI (1) | SI2757103T1 (hr) |
| SM (1) | SMT201600071B (hr) |
| TW (1) | TWI543975B (hr) |
| UA (1) | UA112873C2 (hr) |
| WO (1) | WO2013039057A1 (hr) |
| ZA (1) | ZA201400918B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9550732B2 (en) * | 2013-03-12 | 2017-01-24 | Eisai R&D Management Co., Ltd. | Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof |
| WO2014142086A1 (ja) * | 2013-03-13 | 2014-09-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピロリジン－３－イル酢酸誘導体およびピペリジン－３－イル酢酸誘導体 |
| US20240199558A1 (en) | 2022-10-19 | 2024-06-20 | Astrazeneca Ab | 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx3cr1 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4263391B2 (ja) | 2001-03-19 | 2009-05-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用 |
| WO2003037271A2 (en) * | 2001-10-30 | 2003-05-08 | Millennium Pharmaceuticals,Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| JP2007507494A (ja) * | 2003-10-07 | 2007-03-29 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体アンタゴニストとりわけＣＸ３ＣＲ１として有用な新規な２−置換４−アミノ−チアゾロ［４，５−ｄ］ピリミジン |
| UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| AR053347A1 (es) * | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| MX2009003003A (es) | 2006-09-29 | 2009-04-01 | Astrazeneca Ab | Nuevos derivados de [1,3]tiazolo [4,5-d]pirimidin-2-(3h)-amina 5,7-disustituidos y su uso en terapia. |
| TW200820973A (en) | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
| CL2007002958A1 (es) | 2006-10-12 | 2008-05-09 | Epix Delaware Inc | Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr |
| KR101581829B1 (ko) * | 2008-03-07 | 2015-12-31 | 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 | 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1 및 ｃｘ3ｃｒ1의 발현을 기초로 한 질환들의 치료에서 이의 용도 |
| AR071036A1 (es) | 2008-03-26 | 2010-05-19 | Astrazeneca Ab | Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1. |
-
2012
- 2012-09-05 JO JOP/2012/0251A patent/JO3082B1/ar active
- 2012-09-05 TW TW101132401A patent/TWI543975B/zh not_active IP Right Cessation
- 2012-09-06 AR ARP120103280A patent/AR087788A1/es active IP Right Grant
- 2012-09-11 CN CN201280041634.0A patent/CN103764648B/zh not_active Expired - Fee Related
- 2012-09-11 HU HUE12831085A patent/HUE026824T2/en unknown
- 2012-09-11 RS RS20160106A patent/RS54582B1/en unknown
- 2012-09-11 MX MX2014002210A patent/MX358494B/es active IP Right Grant
- 2012-09-11 JP JP2013533669A patent/JP5829689B2/ja not_active Expired - Fee Related
- 2012-09-11 PL PL12831085T patent/PL2757103T3/pl unknown
- 2012-09-11 ME MEP-2016-37A patent/ME02383B/me unknown
- 2012-09-11 PT PT128310851T patent/PT2757103E/pt unknown
- 2012-09-11 SG SG11201400163WA patent/SG11201400163WA/en unknown
- 2012-09-11 CA CA2844617A patent/CA2844617C/en active Active
- 2012-09-11 WO PCT/JP2012/073171 patent/WO2013039057A1/ja active Application Filing
- 2012-09-11 AU AU2012309556A patent/AU2012309556B2/en not_active Ceased
- 2012-09-11 EP EP12831085.1A patent/EP2757103B1/en active Active
- 2012-09-11 ES ES12831085.1T patent/ES2564732T3/es active Active
- 2012-09-11 MY MYPI2014700213A patent/MY169869A/en unknown
- 2012-09-11 PE PE2014000266A patent/PE20141353A1/es active IP Right Grant
- 2012-09-11 BR BR112014004267-5A patent/BR112014004267B1/pt not_active IP Right Cessation
- 2012-09-11 SI SI201230463T patent/SI2757103T1/sl unknown
- 2012-09-11 RU RU2014107536A patent/RU2615135C2/ru active
- 2012-09-11 DK DK12831085.1T patent/DK2757103T3/en active
- 2012-09-11 KR KR1020147003630A patent/KR101963922B1/ko active IP Right Grant
- 2012-11-09 UA UAA201401661A patent/UA112873C2/uk unknown
-
2014
- 2014-02-03 IL IL230804A patent/IL230804A/en active IP Right Grant
- 2014-02-06 ZA ZA2014/00918A patent/ZA201400918B/en unknown
- 2014-02-27 CL CL2014000484A patent/CL2014000484A1/es unknown
- 2014-07-04 HK HK14106800.1A patent/HK1193407A1/xx not_active IP Right Cessation
-
2016
- 2016-02-16 HR HRP20160166TT patent/HRP20160166T1/hr unknown
- 2016-03-10 SM SM201600071T patent/SMT201600071B/xx unknown
- 2016-03-16 CY CY20161100224T patent/CY1117460T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
| HRP20150704T1 (hr) | Derivati piperidinona kao mdm2-inhibitori za lijeäśenje raka | |
| JP2014516360A5 (hr) | ||
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| EA201001455A1 (ru) | Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3) | |
| HRP20160166T1 (hr) | Derivat pirolidin-3-iloctene kiseline | |
| EA201200259A1 (ru) | Гетероциклы с микробиоцидными свойствами | |
| PL415078A1 (pl) | Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków | |
| PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| AR059425A1 (es) | Amidas ciclicas condensadas del acido bencensulfonico, un metodo para su preparacion, composiciones farmaceuticas que las contienen y el empleo de las mismas en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de l-cpt1 | |
| NZ708593A (en) | Novel pyrazole derivative | |
| CA2672373A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| NZ594930A (en) | Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1 | |
| ECSP10010336A (es) | Derivados de piridina | |
| EA201300436A1 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| WO2010007316A3 (fr) | NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET | |
| HK1202237A1 (zh) | -二氯- -苯並 咪唑- -基 -吡唑- -羧酸的葡甲胺鹽製劑 | |
| NZ620635A (en) | Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi | |
| HRP20210320T1 (hr) | Spojevi heteroarila za liječenje oftalmičkih bolesti | |
| JP2010510202A5 (hr) | ||
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| CR20140462A (es) | Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil} amino) -1-hidroxietil]-8-hidroquinolin-2(1h)-ona | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| HRP20201932T4 (hr) | Stimulatori / aktivatori topive gvanilat-ciklaze u kombinaciji s nep-inhibitorom i/ili angiotenzin aii-antagonistom i njihova uporaba | |
| MX2019004967A (es) | Sales de derivado de indazol y cristales de las mismas. |